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Abstract 
Background: Extremely low frequency pulsed magnetic fields (ELFPMF) have been 
shown to induce Faraday currents and measurable effects on biological systems. A 
kind of very high frequency electromagnetic field was reported that it improved the 
symptoms of diabetic nephropathy (DN) which is a major complication of diabetes. 
However, few studies have examined the effects of ELFPMF DN at the present. The pre-
sent study was designed to investigate the effects of ELFPMF on DN in streptozotocin 
(STZ)–induced type 1 diabetic rats.
Methods: Adult male SD rats were randomly divided into three weight-matched 
groups: Control (non-diabetic rats without DN), DN + ELFPMF (diabetic rats with DN 
exposed to ELFPMF, 8 h/days, 6 weeks) and DN (diabetic rats with DN exposed to sham 
ELFPMF). Renal morphology was examined by light and electron microscopy, vascular 
endothelial growth factor (VEGF)-A and connective tissue growth factor (CTGF) were 
measured by enzyme linked immune sorbent assay.
Results: After 6 weeks’ ELFPMF exposure, alterations of hyperglycemia and weight loss 
in STZ-treated rats with DN were not found, while both positive and negative effects 
of ELFPMF on the development of DN in diabetic rats were observed. The positive one 
was that ELFPMF exposure attenuated the pathological alterations in renal structure 
observed in STZ-treated rats with DN, which were demonstrated by slighter glomerular 
and tubule-interstitial lesions examined by light microscopy and slighter damage to 
glomerular basement membrane and podocyte foot processes examined by electron 
microscopy. And then, the negative one was that ELFPMF stimulation statistically sig-
nificantly decreased renal expression of VEGF-A and statistically significantly increased 
renal expression of CTGF in diabetic rats with DN, which might partially aggravate the 
symptoms of DN.
Conclusion: Both positive and negative effects of ELFPMF on the development of 
DN in diabetic rats were observed. The positive effect induced by ELFPMF might play 
a dominant role in the procession of DN in diabetic rats, and it is suggested that the 
positive effect should be derived from the correction of pathogenic diabetes-induced 
mediators.
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Background
Diabetic nephropathy (DN) is a major complication of diabetes [1]. Approximately 
20–40 % of patients with type 1 or type 2 diabetes mellitus develop DN [2]. DN is the 
leading cause of chronic kidney disease accounting for nearly 50 % of all end-stage renal 
disease worldwide [3]. DN is characterized by increased glomerular permeability to 
proteins and excessive extracellular matrix accumulation in the mesangium, eventually 
resulting in glomerulosclerosis and progressive renal impairment [4].
The increasing prevalence of DN worldwide represents a major societal issue because 
of the enormous expense associated with kidney replacement therapy [5]. Current ther-
apies that aim to lower blood glucose are not effective in blocking renal damage, and 
cotreatment with renoprotective drugs often results in potential toxicity, poor tolerabil-
ity and ineffectiveness for some percent of diabetic patients [6]. Therefore, there is an 
urgent need to explore other non-pharmacological novel therapeutic modalities with 
efficacy and safety, particularly when patients with DN require a combined treatment 
with an oral renoprotective drug to preserve normal renal function and to prevent or 
slow the progression of DN.
Near infrared light is a kind of extremely high frequency electromagnetic wave, which 
has much higher frequency than ELFPMF. A study has reported that a near infrared light 
(670  nm low-level light) improved renal function and antioxidant defense capabilities 
in the kidney of streptozotocin (STZ)–induced type 1 diabetic rats [7]. Near infrared 
light and ELFPMF have very different effects in their interaction with living tissue, while 
ELFPMF is more widely studied than near infrared light in biological systems by our 
literature review. According to our literature review, ELFPMF has been shown to induce 
non-thermal effects on biological systems [8]. However, few studies have examined the 
effects of ELFPMF on DN at the present. Therefore, we aimed to investigate the effects 
of ELFPMF on kidney complications induced by diabetes.
In the current study, we used STZ-treated diabetic rats with DN to assess the effects 
of whole-body exposure to 15 Hz ELFPMF whose peak magnetic flux density (MFD) was 
approximate 1.6 × 10−3 T on the development of renal changes in DN by using morpho-
logical examination and ELISA analysis for VEGF-A and CTGF. The ELFPMF was gen-
erated by a self-produced apparatus and the exposure duration was 8 h per day, 6 days a 
week for 6 weeks. Our results demonstrate that ELFPMF had two-sided effects on renal 
damage induced by diabetes.
Methods
Experimental diabetes
Thirty-two adult male Sprague–Dawley rats, weighting 300 ±  20  g, were provided by 
Animal Center of the Fourth Military Medical University and housed in a room (Ani-
mal Center of the Fourth Military Medical University, Xi’an, China) with controlled 
temperature (23 ± 1 °C), relative humidity (50 ~ 60 %), and alternately light–dark cycle 
(12  h/12  h), with access to standard pellet and clean water. Eight rats were treated as 
non-diabetic control animals, and the rest 24 rats were used to induce diabetic mod-
els. Diabetes mellitus was induced by an intraperitoneal injection of STZ (55  mg/kg 
body weight) in freshly prepared citrate buffer (pH 4.5) after an overnight fast. Simi-
larly, equivalent dose of sterile citrate buffer solution was injected into the control rats. 
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Confirmation of hyperglycemia was made three days after STZ injection, and only 
STZ-treated rats whose glucose concentration of the tail venous blood measured by 
OneTouch SureStep Plus glucometer (Lifescan, Milpitas, CA, USA) were higher than 
20 mmol/L were considered as qualified diabetic models [9]. Eight rats were excluded 
from the qualified diabetic models because of low blood glucose levels. The rest of rats 
were randomized into three weight-matched groups (eight in each group): non-diabetic 
rats without DN control group (Control), diabetic rats with DN exposed to ELFPMF 
group (DN + ELFPMF) which were subjected to whole-body exposure to 15 Hz ELFPMF 
8 h (09:00–17:00) everyday, 6 days a week for 6 weeks and diabetic rats with DN exposed 
to sham ELFPMF exposure group (DN). Although the same ELFPMF apparatus was 
employed in DN group, the ELFPMF stimulator was not activated. ELFPMF stimula-
tion was carried out the next day after confirmation of hyperglycemia. The current study 
was performed in adherence to the National Institutes of Health guidelines for the use 
of experimental animals, and all animal protocols were approved by the Committee for 
Ethical Use of Experimental Animals of the Fourth Military Medical University.
ELFPMF apparatus
The ELFPMF exposure system (GHY-III, FMMU, Xi’an, China; China Patent 
no.ZL02224739.4) was composed of a pulsed signal generator (Fig. 1b) and a modified 
Helmholtz coils assembled with three-coil array. This apparatus has presented has been 
described in detail in our previous study [10].
The modified Helmholtz coils was composed of three identical coils which were in 
series connection, with the same coil diameters of 800  mm and placed coaxially with 
a distance of 304  mm apart. Each coil was made up of enameled coated copper wire 
Fig. 1 Schematic drawing of the ELFPMF apparatus and pulse protocol. a Modified Helmholtz coils assem-
bled with three-coil array. b The pulsed signal generator GHY-III. c The open-circuit voltage waveform gener-
ated by GHY- III with a repetitive burst frequency at 15 Hz (burst width, 5 ms; burst wait, 60 ms; pulse width, 
0.2 ms; pulse wait, 0.02 ms; pulse rise and fall time: 0.3, 2.0 μs)
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with 0.8 mm diameter. The number of turns of the central coil was 266, and the num-
ber of turns of the two outside coils was 500 (Fig.  1a). The modified Helmholtz con-
figured with these parameters has presented significantly upgraded uniformity of MFD 
[10]. As depicted in Fig. 1c, the pulsed signal apparatus generated an open circuit wave-
form which was composed of a pulsed burst (burst width, 5 ms; burst wait, 60 ms; pulse 
width, 0.2 ms; pulse wait, 0.02 ms; pulse rise and fall time: 0.3, 2.0 μs) repeated at 15 Hz. 
This type of waveform has been proved effective in the prevention and treatment of 
bone disorders, cardiovascular and neurological diseases by our research group over a 
long period of time [10–12].
Two cubic plastic rat cages containing rats in DN + ELFPMF group were put in the 
center of every two neighboring coils (the length of the cage was along O–Y direction) 
and cages were supported by stands to let the activities of rats restrict on the XY plane 
which had higher intensity and better uniformity of MFD (Fig.  1). The distribution of 
the peak MFD was measured by using a Gaussmeter (Model 455 DMP Gaussmeter, 
Lake Shore Cryotronics, USA), and the measurement result was (1.6 ± 0.1) × 10−3 T 
(mean ± SD) in the exposure area (cage: 50 cm long, 20 cm wide and 15 cm high).
Measurements of weights and blood glucose levels
The weights and blood glucose levels of all rats were evaluated prior to STZ administra-
tion, and there were no statistically significant differences for these parameters among 
three groups. In addition, weights and blood glucose levels of all rats were measured 
after 6-week ELFPMF exposure period.
Get the tissue samples
Six weeks after ELFPMF stimulation in STZ-treated rats with DN, all rats were anesthe-
tized by an intraperitoneal injection of 7 % chloral hydrate solution (0.45 ml/100 g) prior 
to collecting the kidney. Both kidneys for each rat were harvested and blotted. Left or 
right kidney for each rat was randomly chosen to carry morphological examination and 
ELISA analysis respectively.
Light microscopy of renal morphology
The renal cortex samples were fixed by immersion in 10  % neutral buffered formalin. 
After being embedded in paraffin, 4 μm sections were stained with hematoxylin-eosin 
(HE), periodic acid Schiff (PAS), and Masson’s trichrome. Two sections for every stain-
ing method were got per rat, and five different sites of renal glomeruli were viewed per 
section. All the slides were examined by a renal pathologist (YW) in single blind fashion.
Ultrastructural examination of renal glomeruli
The renal cortex was dissected and post fixed by immersion in the fixative solution (2 % 
paraformaldehyde, 2 % glutaraldehyde, 0.1 M cacodylate buffer at pH 7.3) for 2 h at 4 °C, 
and washed in 0.1 M cacodylate buffer, and osmicated for 4 h in 1 % OsO4 (Fluka). Sec-
tions of renal cortex were rinsed in 0.1 M cacodylate buffer, dehydrated and embedded 
in epoxy 812-Araldite (Polysciences). Ultra-thin sections (80 nm) were subsequently cut, 
collected on cellodincoated single slot grids and stained with uranyl acetate and lead 
citrate. The microphotographs were obtained using a transmission electron microscope 
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(JEM-1230, Japan) operated at 80 keV, and the thickness of glomerular basement mem-
brane (GBM) was measured using the ruler function of the software. Average GBM 
thickness for each rat was calculated from 30 measurements obtained from different 
sites of GBM, and eight rats were chosen to evaluate the thickness of GBM for each 
group.
ELISA
After cutting kidney cortex samples, we checked the weight, added PBS (pH 7.2–7.4), 
rapidly frozen with liquid nitrogen, maintained samples at 2–8 °C after melting, added 
PBS (pH 7.4), homogenized by grinders, carried centrifugation 20-min at the speed of 
2000–3000 r.p.m. and finally removed the supernatant.
Assays were performed in 48-well immunoplates (Chemicon International). ELISA 
analyses for VEGF-A and CTGF were performed using commercially available kits for 
rat VEGF-A (Yonghui Biotechnology Co., Ltd, Beijing, China) and rat CTGF (Yong-
hui Biotechnology Co., Ltd, Beijing, China) respectively. Experiments were performed 
according to the manufacturers’ instructions [13].
Statistics
Statistical analyses were carried out using SPSS (version 14.0, SPSS, IL, USA). All val-
ues were expressed as mean ± SD. P < 0.05 was considered statistically significant. All 
data sets were independent, normally distributed, and with equal variance. Comparisons 
between multiple groups were performed by one-way ANOVA followed by Bonferroni’s 
post hoc test.
Results
Body weights and whole blood glucose levels
After 6-week diabetic period, as shown in Fig.  2, One-way ANOVA with Bonferroni’s 
post hoc determined that the mean body weight of DN group and DN  +  ELFPMF 
group were statistically significantly lower than that in the Control group (P  <  0.05). 
After STZ injection, rats consistently lost weight. Although there was slightly less loss 
of the body weight in ELFPMF treated diabetic rats, no significant difference between 
DN + ELFPMF group and DN group was found (P > 0.05). Six weeks’ ELFPMF stimu-
lation did not statistically significantly affect the loss of body weight caused by diabe-
tes. Similarly, after 6-week diabetic period, one-way ANOVA with Bonferroni’s post 
hoc revealed that the average blood glucose levels of DN group and DN  +  ELFPMF 
group were statistically significantly higher than that in the Control group (P  <  0.05) 
(Fig.  3). STZ administration caused a rapid elevation of average blood glucose levels 
(>27.8 mmol/L) within one week, which persisted for up to 6 weeks. Although the blood 
glucose levels were slightly lower in ELFPMF treated diabetic rats, there was no sig-
nificant difference between DN + ELFPMF group and DN group (P > 0.05). Six weeks’ 
ELFPMF stimulation did not statistically significantly affect the hyperglycemia caused by 
diabetes.
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Light microscopy
Glomerular lesions were observed in HE-stained tissue sections from STZ-injected rats 
at the end of the 6-week experimental period (Fig. 4, HE panel). Glomerular hypertrophy 
and mesangial matrix expansion were observed in the DN group at the end of the 6-week 
experiment period. However, these changes were ameliorated in the DN  +  ELFPMF 
group compared with DN group. Treatment with ELFPMF partially restored the normal 
morphology of glomeruli in diabetic rats (Fig. 4, HE panel).
Glycogen deposition in the glomeruli was measured by PAS staining to indicate the 
severity of glomerulosclerosis. PAS staining showed STZ-induced glomerulosclerosis, 
which was partially improved in ELFPMF treated diabetic rats (Fig. 4, PAS panel).
Since extracellular matrix deposition is another hallmark of glomerulosclerosis, col-
lagen was visualized using Masson’s trichrome staining (Fig. 4, Trichrome panel). STZ 
treatment resulted in collagen accumulation inside glomeruli or in the periglomerular 
area, which was reduced in ELFPMF treated group.
Fig. 2 Scatter plot for weights of STZ-induced diabetic rats with DN after 6-week exposure to ELFPMF. Plot is 
expressed as mean ± SD (n = 8), *P < 0.05 vs Control group
Fig. 3 Scatter plot for blood glucose levels of STZ-induced diabetic rats with DN after 6-week exposure to 
ELFPMF. Plot is expressed as mean ± SD (n = 8), *P < 0.05 vs Control group
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These results clearly demonstrate that these diabetic rats develop glomerular hyper-
trophy, glomerular extracellular matrix accumulation, increasement of GBM thickness 
and mesangial proliferation within 6 weeks after diabetes debut. What’s more, the results 
from our study also revealed the ability of ELFPMF treatment to attenuate STZ-induced 
pathological alterations in renal structure during the progression of DN.
Electron microscopy
Ultrastructural examination of glomeruli was obtained by using transmission electron 
microscopy after 6-week experimental period in all rats. In Control group, glomeruli 
with normal structure and morphology were observed and podocyte foot processes 
were regularly shaped (Fig. 5a). Glomeruli from diabetic rats displayed some degree of 
thickness of the GBM which has been an independent criterion for glomerulosclerosis 
(Fig. 5b, arrow, d). What’s more, effacement and confluence of podocyte foot processes 
were observed in DN group (Fig. 5b). In DN + ELFPMF group, glomeruli and podocyte 
foot processes were abnormal, but the damage was slighter than that in the DN group 
(Fig. 5c). Especially, the thickness of GBM was improved by 6-week ELFPMF exposure 
(Fig. 5d).
Fig. 4 Representative glomeruli from Control, DN, and DN + ELFPMF groups after 6-week experimental 
period (magnification: ×400). Renal cortex sections were stained with hematoxylin-eosin (HE), periodic acid 
Schiff (PAS), and Masson’s trichrome
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Effects of ELFPMF on renal expression of VEGF‑A
Bonferroni-adjusted pairwise comparisons revealed that the renal expression of VEGF-
A in DN group and DN  +  ELFPMF group were statistically significantly lower than 
that in the Control group (P  <  0.01) (Fig.  6). The renal expression of VEGF-A signifi-
cantly decreased in diabetic rats compared to that in the non-diabetic rats. In addition, 
the renal expression of VEGF-A in DN + ELFPMF group was statistically significantly 
lower than that in the DN group (P < 0.05) (Fig. 6). ELFPMF stimulation significantly 
decreased the renal expression of VEGF-A in diabetic rats.
Effects of ELFPMF on renal expression of CTGF
Bonferroni-adjusted pairwise comparisons revealed that the renal expression of CTGF 
in DN group and DN + ELFPMF group were statistically significantly higher than that 
in the Control group (P  <  0.01) (Fig.  7). The renal expression of CTGF significantly 
increased in the diabetic rats compared to that in the non-diabetic rats. In addition, the 
renal expression of CTGF in DN + ELFPMF group was statistically significantly higher 
Fig. 5 Electron microscopy of the GBM and podocyte foot processes in Control, DN, and DN + ELFPMF 
groups after 6-week experimental period are displayed (magnification: ×10,000). a Control group: glomeruli 
with normal structure and morphology were observed and podocyte foot processes were regularly shaped. 
b DN group: Glomeruli from diabetic rats displayed some degree of thickness of the GBM, effacement and 
confluence of podocyte foot processes were also observed. c DN + ELFPMF group: glomeruli and podocyte 
foot processes were abnormal, but the damage was slighter than that in DN group. d Scatter plot for GBM 
thickness in Control, DN, and DN + ELFPMF groups are plotted as mean ± SD (n = 8 per group). The mean 
value of GBM thickness measured at 30 different sites was considered as the GBM per rat. *P < 0.05 vs Control 
group, #P < 0.05 vs DN group
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than that in the DN group (P < 0.05) (Fig. 7). ELFPMF stimulation significantly increased 
the renal expression of CTGF in diabetic rats.
Discussion
In the current investigation, a marked decrease in body weight of diabetic rats was 
observed 6 weeks after the debut of diabetes as compared to that in non-diabetic con-
trol rats. The reduction in body weight is probably related to the osmotic diuresis 
and dehydration induced by diabetic hyperglycemia [14]. Meanwhile, blood glucose 
level rose immediately after the STZ injection, reached quite a high level at first week 
(>27.8 mmol/L), and then remained approximately at 27 mmol/L. The results of the cur-
rent study have confirmed previous findings that blood glucose level elevated and body 
weight decreased in diabetic rats after STZ administration [15]. Our results also revealed 
that ELFPMF stimulation did not statistically significantly prevent the weight loss caused 
by diabetes, which is consistent to our and others’ previous investigation [10, 14]. How-
ever, contrary to the findings researched by Mert [14] and Jing [11] who observed that 
Fig. 6 ELISA analysis for VEGF-A expression in renal cortex in Control, DN, and DN + ELFPMF groups after 
6-week experimental period (n = 8). *P < 0.05 vs Control group; #P < 0.05 vs DM group
Fig. 7 ELISA analysis for CTGF expression in renal cortex in Control, DN, and DN + ELFPMF groups after 
6-week experimental period (n = 8). *P < 0.05 vs Control group; #P < 0.05 vs DM group
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ELFPMF had efficacy in anti-hyperglycemia in diabetic rats, we found that the appli-
cation of ELFPMF did not statistically significantly alter hyperglycemia in diabetic rats 
during the whole experimental period (6  weeks). The different effects of ELFPMF on 
hyperglycemia might be ascribed to the different standards for diabetic model adopted 
by us and them. The higher standards (>20 mmol/L) for diabetic model adopted by us 
than Mert’s and Jing’s (>16.7 mmol/L) might cause a severe damage which could not be 
reversed by ELFPMF.
Obviously, a prerequisite for a clear understanding of the pathophysiological mecha-
nisms of nephropathic appearance and treatment is to know if there are definite struc-
tural changes in the kidney and to what extent they exist in the patients or experimental 
animal models. The pathology of DN is characterized by increased glomerular perme-
ability to proteins and excessive extracellular matrix accumulation in the mesangium, 
eventually resulting in glomerulosclerosis and progressive renal impairment [3, 4]. In 
the present study, some evidences of pathological alterations of the glomerulus such as 
progressive glomerular hypertrophy, mesangial matrix expansion, thickened GBM and 
effacement and confluence of podocyte foot processes were observed in STZ-treated 
rats with DN. Similar results were also reported by other investigators [16, 17]. In addi-
tion to this, our morphological study of kidney revealed that long-term ELFPMF stimu-
lation partially prevented or slowed the progression of DN in STZ-treated rats, which 
appears to be seldom reported in animal models for DN by other investigators.
Our findings confirm earlier studies on kidney biopsies from diabetes patients and 
other glomerular diseases in which VEGF-A expression was also decreased in the 
glomeruli [18]. Similarly, another study also reported that glomerular expression of 
VEGF-A was reduced 1 week after STZ induction [19]. It is more likely that the down-
regulation of VEGF-A, results from a reduction of insulin secretion caused by strepto-
zotocin in different disease stages [20]. What’s more, VEGF-A is normally produced by 
podocytes, and podocyte loss observed by ultrastructural examination of glomeruli in 
our study might also cause down-regulation of VEGF-A [21, 22]. However, this would 
seem to contradict an experimental study on diabetic rats in which VEGF-A mRNA 
levels in the cortex and glomeruli were increased [23]. The reason for the differences 
between our findings and those reported in the literature may be that the shorter dura-
tion of disease studied than theirs [24]. In addition to this, our results also revealed that 
ELFPMF stimulation significantly decreased the renal expression of VEGF-A in diabetic 
rats, and the down-regulation of VEGF-A induced by ELFPMF is similarly reported by 
our previous study and other investigators [10, 12].
Glomerular hypertrophy and accumulation of extracellular matrix components, which 
is mediated predominantly by the prosclerotic cytokines TGF-β and CTGF, are other 
characteristic features of DN [4]. In our study, after 6 weeks of STZ-induced diabetes, 
there was a significant increase in expression of CTGF in rat renal cortex. Our data 
on expression of CTGF in renal cortex are in agreement with previously studies which 
reported that overexpression of CTGF at the mRNA or protein level has previously been 
demonstrated in vivo in experimental diabetic rats [25] and human kidney with DN [26], 
as well as in cultured high glucose stimulated HK-2 cells [27]. What’s more, our results 
also revealed that 6-week administration of ELFPMF statistically significantly increased 
the expression of CTGF measured by ELISA. The effects of ELFPMF on expression of 
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CTGF in our study are similar to other investigations which reported that ELFPMF 
could promote extracellular matrix production and mineralization in osteoblastlike cells 
[28] and accelerate extracellular matrix synthesis in connective tissue [29].
In our study, the down-regulation of VEGF-A and up-regulation of CTGF induced by 
6-week ELFPMF exposure in renal cortex indicate that ELFPMF might aggravate the 
symptoms of DN. However, actually, 6-week exposure to ELFPMF stimulation partially 
prevented the development of glomeruli degeneration in STZ-treated rats with DN by 
using morphological examinations. Therefore, we hypothesized that although the regu-
lation of VEGF-A and CTGF induced by ELFPMF might partially aggravate the devel-
opment of DN, ELFPMF might ameliorate kidney complications induced by diabetes 
through other mechanisms, because the pathogenesis of DN is complex and involves mul-
tiple pathways that lead to kidney injury, including the polyol pathway [30], protein kinase 
C [31], advanced glycation end products [32], high glucose-induced generation of reac-
tive oxygen species (ROS) [33], and proinflammatory cytokines. These diabetes-induced 
mediators interact in their adverse effects on the kidney. In addition, suppression of ROS 
production [34] and anti-inflammatory [35, 36] effects have been found by numerous 
studies. Therefore, it is not surprising that correction of any of them by ELFPMF results 
in amelioration of DN. Therefore, we would argue that long-term ELFPMF stimulation 
might ameliorate kidney complications in diabetic rats by correction of pathogenic dia-
betes-induced mediators, which might lead to slighter glomerular and tubulointerstitial 
lesions compared to those of the DN group observed in the present study.
Conclusions
It is suggested that ELFPMF might have two kinds of effects on diabetic rats with DN. 
One is negative effect, which is demonstrated by statistically significantly decreased 
renal expression of VEGF-A and significantly increased renal expression of CTGF in 
diabetic rats, and the other is positive effect, which is inferred from the slighter patho-
logical alterations in renal structure in DN +  ELFPMF group than that in DN group. 
More importantly, the positive effect induced by ELFPMF might play a dominant role 
in the procession of DN in diabetic rats, and this positive effect induced by ELFPMF 
might result from correction of pathogenic diabetes-induced mediators. However, fur-
ther research is required to elucidate the specific mechanisms for the two-sided effects 
of ELFPMF on DN.
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